Impact on spina bifida screening of shifting prenatal Down syndrome maternal serum screening from the second trimester to the first
- 28 April 2017
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 37 (7) , 673-679
Abstract
Objectives: Shifting screening for trisomy 21 to the first trimester has resulted in the loss of maternal serum alpha‐fetoprotein screening for spina bifida. The aim of this study was to study the impact on open spina bifida prenatal screening.Study design: We reviewed prenatally diagnosed cases of spina bifida over three years: 2009 (only second‐trimester screening, MSM2T), 2010 (transient period) and 2011 (majority first‐trimester screening, MSM1T). Cases were assigned to three groups based on maternal serum markers (MSM2T, MSM1T and ‘not performed’). Gestational age at diagnosis of spina bifida was compared between these three groups and between the years 2009 and 2011.Results: Median gestational ages at diagnosis of the 742 spina bifida cases between the three groups were 22 weeks [18+6–23], 22+1 weeks [21+3–23] and 21+4 weeks [14+1–23], respectively (P < 0.005). The diagnosis was made at 14–20 weeks in 34.7% for MSM2T group versus 8.5% for MSM1T (P < 0.001). Spina bifida diagnosis at 14–20 weeks declined from 38.8% in 2009 to 13.3% in 2011 (P < 0.001).Conclusion: Loss of maternal serum alpha‐fetoprotein had a tangible effect on the gestational age at diagnosis of spina bifida and resulted in a decrease of 25% of cases of spina bifida detected before 20 weeks. © 2017 John Wiley & Sons, Ltd.Keywords
Funding Information
- Agence de la Biomedecine, (Project SPINALPHA N°13-18/89)
This publication has 28 references indexed in Scilit:
- Combined screening for open spina bifida at 11-13 weeks using fetal biparietal diameter and maternal serum markersAmerican Journal of Obstetrics and Gynecology, 2013
- Biparietal diameter at 11–13 weeks' gestation in fetuses with open spina bifidaUltrasound in Obstetrics & Gynecology, 2013
- Assessment of intracranial translucency (IT) in the detection of spina bifida at the 11–13‐week scanUltrasound in Obstetrics & Gynecology, 2009
- First-Trimester or Second-Trimester Screening, or Both, for Down's SyndromeNew England Journal of Medicine, 2005
- Second trimester trisomy 21 maternal serum marker screening. Results of a countrywide study of 854 902 patientsPrenatal Diagnosis, 2002
- Neural-Tube DefectsNew England Journal of Medicine, 1999
- Prediction of adverse perinatal outcome by maternal serum screening for down syndrome in an asian populationObstetrics & Gynecology, 1997
- ULTRASOUND SCREENING FOR SPINA BIFIDA: CRANIAL AND CEREBELLAR SIGNSThe Lancet, 1986
- ORGANISATION OF MATERNAL SERUM-α-FETOPROTEIN SCREENING FOR FETAL NEURAL-TUBE DEFECTSThe Lancet, 1977
- PRENATAL DIAGNOSIS OF SPINA BIFIDA AND ANENCEPHALY THROUGH MATERNAL PLASMA-ALPHA-FETOPROTEIN MEASUREMENTThe Lancet, 1974